Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhagoDAIR I phage therapy pilot study in Staphylococcus aureus prosthetic joint infection
NL-OMON53569Phase 2Withdrawn
- Sponsor
- PHAXIAM Therapeutics
- Start
- Feb 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PP1493 and PP1815 in periprosthetic joint infection (PJI) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoint: Clinical control of infection at Week 12±2. Planned start Feb 2023; status: withdrawn.
02
Drugs
PP1493PP1815
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NL-OMON53569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53569.